by Carlos A.
Garcia-Etienne, Robert E. Mansel, Mariano Tomatis, Joerg Heil, Laura Biganzoli,
Alberta Ferrari, Lorenza Marotti, Adele Sgarella, Antonio Ponti, EUSOMA Working
Group
The Breast: June 2019, Volume 45, Pages 89-96
Data from recently
published trials have provided practice-changing recommendations for the
surgical approach to the axilla in breast cancer. Patients with T1-2 lesions,
treated with breast conservation, who have not received neoadjuvant
chemotherapy and have 1–2 positive sentinel nodes (Z0011-criteria) may avoid
axillary lymph node dissection (ALND). We aim to describe the dissemination of
this practice in Europe over an extended period of time.
